ClinicalTrials.gg
Sign In

Thymoma clinical trials

The registry lists 133 studies for Thymoma across more than 10 countries. 37 are recruiting or about to start. 84 of them are mainly about Thymoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Thymoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
53
Recruiting
25
Active, not recruiting
12
Terminated
12
Status unknown
12
Not yet recruiting
11

Phase

Phase 2
64
Phase 1
21
Phase 3
7
Phase 4
2
Early Phase 1
1

Where

United States
58
China
36
Italy
13
France
8
Netherlands
6
Taiwan
5

Who runs them

National Cancer Institute (NCI) (15) · Fudan University (4) · Georgetown University (3) · Shanghai Pulmonary Hospital, Shanghai, China (3) · Shanghai Zhongshan Hospital (3) · Sun Yat-sen University (3) · M.D. Anderson Cancer Center (3) · Novartis Pharmaceuticals (3)

What is being tested here

Drugs under test in Thymoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Paclitaxel315
Pembrolizumab205
Carboplatin213
Sacituzumab tirumotecan202
Albumin-Bound Paclitaxel212
Cisplatin115
Cyclophosphamide103
Lenvatinib102
Anti-TCR Vb6/Vb10/IL-2 Antibody Fusion Protein STAR0602101
Imifoplatin101

Drug classes tested here Immune checkpoint inhibitors 3 open · Antimitotic agents 3 open · Antibody-drug conjugates (ADCs) 3 open · Tyrosine kinase inhibitors (TKIs) 2 open · Antimetabolites 1 open

Coming up

3phase 3 studies under way
13studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 25 Thymoma studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger. 3 (12%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 25
AgeWomenMen
102 (8%)2 (8%)
1825 (100%)25 (100%)
3025 (100%)25 (100%)
4025 (100%)25 (100%)
5025 (100%)25 (100%)
6525 (100%)25 (100%)
7524 (96%)24 (96%)
8513 (52%)13 (52%)

Across all 133 studies, recruiting or not: 24% stop at 75 or younger and 2% at 65; 8% take children; 0% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Thymoma studies take

Of 32 phase 2 interventional studies under Thymoma, half reached primary completion within 59 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 259 mo36–96 · 32 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Stopped1

Newly registered2

Studies

Recruiting first, then most recently updated. Showing 50 of 133. Browse all 133 → or search them.